Expert Interview
A Second Look: Discussing Spruce Biosciences’ Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B
Ticker(s): SPRBInstitution: University of Minnesota Medical School
- Professor of Pediatrics and Experimental & Clinical Pharmacology
- Manages hundreds of patients with Sanfilippo Syndrome Type B (MPS IIIB)
- International leader in lysosomal and metabolic diseases, focusing on development of therapies for mucopolysaccharidoses and related lysosomal storage disorders, including pioneering work in bone marrow transplantation, enzyme replacement strategies, and early clinical trials of gene therapy; leads large collaborative research networks studying diagnosis and treatment of rare genetic diseases
How many patients do you manage with Sanfilippo Syndrome Type B?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Spruce Biosciences’ Tralesinidase Alfa (TA-ERT) as a potential treatment for Sanfilippo Syndrome Type B?
Added By: lilly_adminwhat % of older patients that have progressed might not take this ERT? What prevalence of patients and what % of this disease will you think take this ERT in the US?
Added By: lilly_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Mar 19, 2026
- Call Time
- 01:00 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
